IMA203 showed acceptable tolerability and early clinical activity in PD-1–refractory metastatic melanoma patients, with no grade 5 adverse events observed.
2025
Inherited Genetic Differences in Cell Energy Centers Predict Resistance to Therapy for Deadly Skin Cancer
Results from a new study help resolve the decade-long mystery of why many patients with the deadliest form of skin cancer do not respond to the latest cancer treatments.
DANTE trial reveals promising outcomes for shortened immunotherapy in advanced melanoma
Reducing the length of immunotherapy treatment for an advanced skin cancer did not significantly diminish disease control when compared to giving treatments over a longer period, according to breakthrough research led by the Universities of Sheffield and Leeds and Sheffield Teaching Hospitals NHS Foundation Trust.
In a First, Mitochondrial Mutation Tied to Melanoma Checkpoint Resistance
It often starts with something small—a dark spot on the skin that looks a little off.